Biogen Could Still Have Massive Upside From Its Alzheimer’s Drug
Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
All Work
Chris Lange
5 Hot IPOs That Should Come Out Ahead of the 2020 Election
Here are some of the biggest and most eagerly awaited companies that are looking to come public ahead of the 2020 election.
How Much Elective Surgeries Have Really Dropped Off During the COVID-19 Pandemic
Many hospitals shut down elective surgeries and other activities to brace for the impact of COVID-19. However, analysis on these shutdowns is yielding some interesting insight.
Why This Apple Analyst Is So Cautious Despite Rising iPhone 12 Visibility
The iPhone 12 launch is just around the corner, and more investors are throwing their money at Apple anticipating a win. However, one analyst is taking a very cautious approach to the upcoming launch.
Why Investors Are Excited About This New Immunotherapy COVID-19 Study
Corvus Pharmaceuticals watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.
Operation Warp Speed Against COVID-19 Ramps Up With Novavax and Regeneron
Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
5 Speculative COVID-19 Stocks That Could Still Surge
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
5 SPAC and Blank Check Stocks That Have Exploded Higher in 2020
24/7 Wall St. has put together a list of special purpose acquisition company stocks and blank check stocks that could win big this year, and these aren’t just the ones involved in sports betting.
Bed Bath & Beyond, Levi Strauss, Walgreens and More Earnings Coming This Week
24/7 Wall St. offers a preview of what to expect from some of the most anticipated quarterly results due this week.
5 FDA COVID-19 Decisions in July Could Make or Break Stocks
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Lemonade Enters the Market With a Bang
Insurance company Lemonade entered the market with a bang on Thursday.
How E-Commerce Is Saving Francesca’s and Could Save Even More Retailers
Francesca’s shares more than doubled on Thursday after the company announced the development of its first mobile e-commerce application.
Why Akero’s Liver (NASH) Treatment Could Take This Stock Much Higher
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
Have Analysts Become Too Positive About Apple’s iPhone 12?
A lot of Apple stock’s recent momentum has been due to the excitement around the upcoming iPhone 12 and 5G. Is there a wave of new purchases of smartphones, personal computers and tablets coming…
Meet the New Frontrunners in the Race for a COVID-19 Vaccine
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
T2 Biosystems Solidifies Its Position as a COVID-19 Stock With New Test
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
FedEx Delivers in Q4, And Then Some
FedEx reported fiscal fourth-quarter financial results after markets closed Tuesday. The firm reported $2.53 in earnings per share (EPS) and $17.4 billion in revenue, compared with consensus estimates that called for $1.52 in EPS…
Zynerba Cannabinoid Investors Must Now Refocus on Treating Autism
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
Is OptiNose the Next Big Coronavirus Stock?
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Why This Parkinson’s Study Could Be Huge
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.